terial artificial chromosome transgenes and genetic knockout models, to elucidate the roles of DNA elements regulating Aicda expression in vivo. This exciting study also provides the impetus for screening for polymorphisms in Aicda that could potentially alter AID expression and predispose people to either immunodeficiency syndromes or cancer.
line. It is also possible that additional positive and negative regulatory regions exist within or beyond the 100-kilobase region analyzed in this study.
Finally, although it was initially thought that AID expression is specific to activated B cell, it is now clear that AID is also expressed in several nonlymphoid cells, such as primary human hepatocellular carcinomas and helicobacterinfected gastric epithelial cells 5 . AID has also been detected in normal oocytes and embryonic stem cells 15 . The physiological relevance of AID expression in these nonlymphoid cells is yet to be determined. But in the absence of any obvious role for AID in nonlymphoid cells, it is possible that its expression is an inadvertent and often unfortunate consequence of an imbalance in the ubiquitous positive and negative regulatory factors that govern Aicda transcription. For example, NF-κB induced in helicobacter-infected cells as an innate immune response could provide the imbalance necessary for Aicda transcription.
In summary, Tran et al. present a comprehensive map of inhibitory and activating factors that regulate Aicda expression. It serves as the foundation for further studies, using bacnot peak before approximately 60 hours after stimulation. Perhaps region 4 provides the initial burst of derepression but is dispensable for maintenance of the activated state. Rapid downregulation of the activating transcription factors could be a safeguard against a toxic buildup of AID. Likewise, how do the repressor proteins E2f and c-Myb regulate Aicda? E2f is a family of proteins that act as both transcriptional activators and repressors. Perhaps during cytokine stimulation an activating E2f protein transiently replaces the inhibitory E2f proteins at the binding sites in region 2 to promote derepression, followed by reestablishment of the repressed state.
Second, do the elements that respond to CIT stimulation in CH12 cells also function in vivo in the context of germinal centers where CSR and SHM occur? The elements that activate Aicda in response to other CSR inducers, such as bacterial lipopolysaccharide, B cellactivation factor, tumor necrosis factor and interferon-γ are not known. It is likely that the influence of additional elements, such as the reported steroid hormone receptor-binding motifs in region 1 (ref. 15) or the region 3 element, could not be unmasked in the CH12 cell Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells I t has been appreciated for some time that CTLA-4 (cytotoxic T lymphocyte antigen 4), a homolog of CD28, is an indispensable negative regulator of peripheral T cell function 1 . The fatal lymphoproliferative phenotype of Ctla4 -/-mice revealed the critical negative regulatory function of CTLA-4 and provided the first evidence that costimulatory receptors could provide negative as well as positive second signals 2, 3 . CTLA-4-deficient mice develop severe myocarditis and pancreatitis and die within the first month of life. This pathology resembles an autoimmune disease and gave impetus to studies investigating the role of CTLA-4 in T cell tolerance and autoimmunity 4 . Although the role of CTLA-4 in regulating peripheral T cell tolerance has become firmly established, there are still many questions regarding how CTLA-4 exerts its key immunoregulatory functions. Among them is the unresolved question of whether or not T cells that infiltrate various tissues in the Ctla4 -/-mice are autoreactive and tissue specific. In this issue of Nature Immunology, Ise et al. show for the first time that the hyperproliferative and destructive T cell populations in CTLA-4-deficient mice are not on autopilot but require specific signals provided by autoantigens to cause tissue damage 5 . Their work points to an important role for CTLA-4 expression by effector T cells in restraining tissue-specific CD4 + T cells from infiltrating, expanding their populations and/or surviving in target organs and provides evidence that CTLA-4 can control the pathogenicity of self-reactive T cell at multiple levels.
Ise et al. analyze the T cell antigen receptor (TCR) repertoire of CTLA-4-deficient T cells by fixing the TCRβ chain of Ctla4 -/-mice (DOβCtla4 -/-mice). DOβCtla4 -/-mice exhibit a pathology similar to but somewhat delayed relative to that of Ctla4 -/-mice. The antigen-specific nature of pathogenic CTLA-4-deficient T cells is suggested by homing studies in which CD4 + T cells from the spleen or affected organs of DOβCtla4 -/-mice are introduced into recipient mice deficient in recombination-activating gene 2. Although the transfer of splenic T cells recapitulates the multiorgan Ctla4 -/-phenotype, T cells in onset and more restricted than that of CTLA-4-null mice 9 .
Ise et al. provide evidence to support the idea of a role for CTLA-4 in controlling T conv cells, exclusive of its role in T reg cells. In these studies, the CTLA-4-expressing, PDIA2-specific T cells are in an environment deficient in recombination-activating gene 2 and do not express Foxp3, which suggests that CTLA-4 expression on T conv cells is sufficient to prevent these cells from becoming pathogenic. However, CTLA-4-expressing T reg cells could also suppress the pathogenicity of CTLA-4-deficient PDIA2-specific T cells. Thus, this work points to dual functions for CTLA-4, acting both on T conv cells and T reg cells.
The work of Ise et al. suggests that particular self-reactive T cells that escape negative selection must either express CTLA-4 themselves or become subject to peripheral control by T reg cells that also depend on CTLA-4 for their function (Fig. 1) . It is not yet settled whether CTLA-4 acts directly on the T cell that expresses it or acts on the antigen-presenting cell, either by binding of the ligand B7 by CTLA-4, which leads to back-signaling into antigen-presenting cells 11, 12 or by down-modulating B7 expression 9 . The finding that CTLA-4 governs a critical tolerance checkpoint that controls T cell entry into and accumulation in target organs opens a novel area of investigation. It will be important to understand how CTLA-4 regulates the balance between pathogenic effector and protective T reg cell responses in nonlymphoid organs. As B7-1 (CD80) and B7-2 (CD86) can be expressed on some nonhematopoietic cells as well as hematopoietic cells, there may exist as-yet-unappreciated cellular interactions by which CTLA-4 defends tissues from pathogenic T cells.
Further understanding of how CTLA-4 regulates tolerance has therapeutic as well as fundamental importance. The critical role of CTLA-4 in human autoimmune disease is underscored by genome-wide association studies that have identified CTLA4 as a key gene associated with the risk of developing many human autoimmune diseases 13 . In addition, CTLA-4 is an important therapeutic target in cancer immunotherapy 14 . The work of Ise et al. suggests a new means by which CTLA-4 may contribute to the multiple barriers that prevent antitumor responses and shield tumors from immune eradication. Better understanding of the levels at which CTLA-4 exerts its inhibitory functions will facilitate the design of therapeutic strategies that target CTLA-4 to treat cancer, autoimmunity, graft rejection and infectious diseases. sion and/or survival in target tissue. A role for CTLA-4 in modulating the dynamics of T cell-antigen-presenting cell interactions has been demonstrated previously, but the focus has been mainly on interactions within the lymph node rather than trafficking into tissues 7 . Further studies are needed to understand how CTLA-4 protects the tissues from pathogenic self-reactive T cells.
The work of Ise et al. also addresses the controversial question of whether expression of CTLA-4 is important only on regulatory T cells (T reg cells) or whether conventional T cells (T conv cells) also require expression of this molecule. T reg cells act in trans to control the responsiveness of T conv cells and other components of the immune system. A role for CTLA-4 in facilitating T reg cell function was first suggested by bone marrow-chimera studies 8 . Specific deletion of CTLA-4 in T reg cells positive for the transcription factor Foxp3 and experiments using a sophisticated blastocyst chimera have unambiguously demonstrated the crucial role of CTLA-4 in T reg cell biology 9, 10 . However, a lack of CTLA-4 on T reg cells does not fully account for the phenotype of CTLA-4-null mice, as specific deletion of CTLA-4 in T reg cells results in a fatal inflammatory pathology that is delayed transferred from affected organs (for example, lungs, heart or pancreas) tend to accumulate in the corresponding organ of the recipient and cause pathology only in this tissue. Ise et al. identify the acinar cell-specific enzyme PDIA2 (protein disulfide isomerase-associated 2) as a specific autoantigen that drives pancreatic pathology in DOβCtla4 -/-mice and find antibodies to PDIA2 in serum from Ctla4 -/-mice. They clone a PDIA2-reactive TCR that endows naive T cells with pancreas-specific reactivity and compare the functions of Clta4 +/+ and Ctla4 -/-PDIA2-specific T cells.
Notably, Clta4 +/+ and Ctla4 -/-PDIA2-specific T cells migrate and accumulate comparably in pancreatic lymph nodes, but CTLA-4 deficiency markedly enhances the infiltration of these T cells into the pancreas. These findings point to a function for CTLA-4 expressed by antigen-specific effector T cells in regulating peripheral tolerance at the level of the tissue and build on published work linking CTLA-4 to the control of activated T cells after secondary encounter with antigen in target tissues in a nonobese diabetic mouse model 6 . Together these studies indicate that CTLA-4 governs a critical tolerance checkpoint that controls self-reactive T cell entry, population expan- Katie vicari M any immune cells participate in the multifactorial and polygenic nature of the autoimmune pathogenesis of insulin-dependent diabetes mellitus, also known as type 1 diabetes or juvenile diabetes. Mononuclear cells infiltrate the pancreatic islets of Langerhans during a variable period of clinically silent chronic inflammation (insulitis), and eventually T cells destroy insulin-producing beta cells. Natural killer (NK) cells are also involved in type 1 diabetes as causative agents as well as protective cells, but the molecular mechanism of their contribution to type 1 diabetes is unknown 1, 2 . In this issue of Nature Immunology, Gur et al. now suggest that the NK cell activating receptor NKp46 recognizes unknown ligands on beta cells, thus leading to NK cell activation, which in turn may participate in beta-cell destruction 3 (Fig. 1a) .
Full-blown type 1 diabetes ensues when most beta cells are destroyed and the pancreas ceases to produce enough insulin. Exogenous insulin must then be administered for life. Weeks or months after insulin treatment starts, patients with type 1 diabetes can experience a variable period of remission known as the 'honeymoon period'; this is thought to result from restored insulin production by residual beta cells. Continued treatment with exogenous insulin is needed to preserve the residual beta cells, which is important because they can still naturally modulate glucose metabolism and would be the obvious source of beta cells in regeneration therapies. Can diabetes onset be prevented or the honeymoon period be prolonged by interfering with progression of the autoimmune pathology? On the basis of exciting new data in two preclinical models in mice, Gur et al. propose that NKp46 may serve as a new target for halting disease progression 3 (Fig. 1b) .
NKp46 is one of three natural cytotoxicity receptors expressed almost exclusively by NK cells, the others being NKp30 and NKp44. Although human NK cells can express all of these receptors, mice express only NKp46. These receptors were discovered on the basis of their recognition of cancer cells 4 . Although the ligands for NKp44 and NKp46 are still elusive, mouse studies have shown NKp46 is physiologically relevant for tumor immunity (lymphoma 5 and melanoma 6 ) and also in the control of influenza infection 7 .
Despite the elusive nature of NKp46 ligands, fusion proteins of NKp46 and immunoglobulin (NKp46-Ig) can be used in histology and flow cytometry to mark cells that express them. Gur et al. make the initial observation that NKp46-Ig fusion proteins unexpectedly stain human and mouse pancreatic beta cells but no other cells in the islets (glucagon-or somatostatin-producing cells) or in the exocrine pancreas. Remarkably, they find that NKp46-Ig fusion proteins stain not only beta cells from nonobese diabetic (NOD) mice, the most commonly used model of diabetes, but also beta cells from normal BALB/c and C57BL/6 mice. Human thyroid and spleen, as well as mouse thyroid, spleen, lungs, muscle and liver, do not stain with the NKp46-Ig fusion proteins. Salivary glands from NOD and BALB/c mice, however, do express NKp46 ligands, although the implication of this is unclear.
NOD mice demonstrate insulitis from 3 weeks of age and, as in humans, diabetes starts after a variable period of chronic inflammation at around 9-12 weeks of age in mice, and most female mice are diabetic by 30 weeks of age. These authors detect putative NKp46 ligands on a sizeable fraction of pancreatic beta cells (22-81%, depending on the fusion protein used) in BALB/c and C57BL/6 mice and 8-week-old prediabetic NOD mice. Interestingly, NKp46 ligands are not the only ligands on beta cells that are susceptible to innate recognition by immune cells. Indeed, beta cells from NOD, BALB/c and C57BL/6 mice also stain with NKG2D-Ig fusion proteins, although two-to fourfold more NOD cells are NKG2D-Ig + than are cells from normal mice. NKG2D is an activating receptor expressed by human and mouse NK cells, as well as by other cytotoxic cells, such as CD8 + and γδ T cells. NKG2D detects stress-induced major histocompatiblity complex class I-like molecules aberrantly expressed during viral infection and tumor transformation. Importantly, blocking NKG2D on T cells deters diabetes progression in mice 8 . Although expression of the NKG2D ligand on beta cells is lower in NOD mice as diabetes progresses, the fraction of beta cells expressing NKp46 ligands remains unchanged, which suggests that potential interactions between NK cells and beta cells are sustained during disease progression. Does the expression of NKp46 ligands have functional consequences on the activity of NK cells in the pancreatic islets? These authors find that incubation of peripheral NK cells from NOD and BALB/c mice with beta cells induces degranulation in a small fraction of NK cells, as detected by staining with antibodies specific for the lysosomal marker LAMP-1 (CD107). Although small, the fraction of CD107 + NK cells is greater in NOD
